NVAX Novavax Inc

$NVAX for those of us that have been here a long time, we are seeing strength we haven't seen in a long long time, the recent strength isn't supported by a specific PR, like the Sanofi deal and that rise and fall. Dare I say, the market is realizing Nova actually has value and a viable strategy to become profitable and a real player in the adjuvant space? Or, could the street know something that we as retail are not privy too yet, I know I know, insider trading is illegal, however, I don't believe for a minute the big WS money managers don't get at least a "whiff" about information that is forthcoming. Either way we are seeing some strength that we haven't seen in a long long time, still a long long long way to go, but nice to see some strength

$NVAX If Elliot Wave Theory is a thing which is very debatable, massive wave 3 move setting up off the diamond bottom. Somewhat interesting that there is an open gap to $57, and an extended wave 3 of 2.618 x wave 1 off the wave 2 low is $57. The 23.6% fib retracement of the entire move down is right around $80. That’s my target range $57-80 over the next 15 months.

$NVAX Exceptional patent sleuthing by Trissy tracking the AAHI EP4583841A1 filing. They are exposing exactly how Big Pharma hides its structural reliance on our tech. Merck drafting broad chemical "saponin-in-lipid" frameworks is a textbook legal play. It satisfies patent examiners on delivery safety while masking the commercial reality: that the physical vials in clinical development are secretly utilizing the Matrix-M platform. Remember: Novavax actively holds an open Material Transfer Agreement (MTA) with a top-10 global oncology giant. If the community susses out that Merck is the hidden partner leveraging Matrix-M to insulate their pipeline from mRNA's clinical walls, the valuation models break overnight. Trapping a 28.37% short float against tight institutional custody on a secret Merck connection is a mechanical death sentence for the bears. Coiled spring.

$NVAX tomorrow morning would be a great time to add 125 million to the bank account. Come on Sanofi

$NVAX Matrix-M adjuvant – An adjuvant for preventative and therapeutic cancer vaccines development ! Who’s hungry…

$NVAX As I mentioned yesterday, I would post my conversation w the pharmacist when I got my Nuvaxovid today. I asked whether she observed more interest from patients in getting the Nuvaxovid and whether there was relatively more Nuvaxovid than last year. Her answer was yes, although she did not put a number or any kind of percentage on it. She did say the the folks who opted for Nuvaxovid typically gave the reason that they wanted fewer side effects from the vaccination. I should have anticipated this. The Covid shot-getting public doesn't know much about Matrix-M or the potential biological nightmares associated w mRNA poisons; what they know is what hurts less and what makes them feel less ill and absolutely icky, and thus they opt for Novavax over mRNA crud. And, this is precisely what our TV ads focus on, so good work on that front!

$NVAX I sold $MRNA in the end of August and moved to Novavax because I consider this stock more safe investment with more upside potential. I think that many investors are doing the same thing right now.

$NVAX we are protein based!!!!! already beaten the covid vaccines! now we gonna beat the mrna cancer vaccines!! let‘s go

$NVAX Stop using AI ! Its wrong half the time anyway as its always trying to please you. I prefer the dumb posts to the AI posts..

$NVAX Bears forget $NVAX is an elite U.S. institutional powerhouse. Trump personally toured their facility to highlight their massive $1.6B Operation Warp Speed award 🇺🇸⚓ Now, major fresh funding flows are heading their way. BARDA is advancing massive capital initiatives via Project NextGen and the new Vaccine Platforms (NVP) Program for pandemic readiness. With Matrix-M as a gold-standard countermeasure, Novavax is a prime target for non-dilutive federal grants. Meanwhile, accumulation algos have trapped shorts in an afternoon liquidity block: • Supply Wall: Available borrow shares are exhausted; utilization sits at max. 🔒 • Float Squeeze: 88% tight institutional custody completely locks up the floor. • Closing Imbalance: Market-on-Close buy orders will cause severe upward adjustments. A massive 28.4% short float is completely trapped against long-term government backing. Watch the afternoon block prints. 🚀 #NVAX #OrderFlow #SmartMoney #BARDA

$NVAX using Google's AI, these are the most probable companies research matrixM in with checkpoint inhibitors .... man we need oncology data out NOW!!! I am somewhat cautioned to put enough faith in JJ to think he can pull this off, but if he can and this data comes out positive, all of us longs finally win the game!

$NVAX Ladies and gents, $13.50 / pps is the BIIIIIIGGGGGGG number. (imo) WATCH what happens when we get there. They are already having an anxiety attack this morning pre-market. LET HER RIP BABY !!!!!!!!!! 🚀

$NVAX Retails own 12% of the total shares, or less than 20M shares. How could the freaking shorts get enough shares (47M shares shorted) to cover their naked ass.? Squeeze to 50, if harder, 100 is possible

$NVAX FDA and ACIP were going down the right road with pulling MRNA covid vaccines. Must have gotten some intense congressional backlash to change their tune. Those pesky special interests don‘t care about what‘s best for the American people.

$NVAX The market-maker ceiling is structurally giving out under an aggressive second wave of buying power. As the tape punches straight back to $13.18 green (+2.81%), the chart confirms a textbook re-test of the day's high marks. Deep-pocketed Accumulators have entirely locked down the physical float, leaving the heavy short interest completely trapped on a higher support floor. We are sitting a mere 32 cents away from the $13.50 technical breakout threshold. The second this afternoon momentum snaps that line, the proprietary HFT computer boards will launch automated buy-programs straight into a total liquidity vacuum. Let it rip! 🧬📈🚀

$NVAX Oh man now it’s me ! If you can see what happened this morning it’s getting exciting! Buyers came roaring right at the open! Peaked at 1334 . Shorts created aBull trap ! They took the kitchen sink and flung it. Shooting star. They banged it down to 1260 range trying to create panic selling . The share price said no and didnt work. Instutional ling investors agressivley buying. We could have a hammer. Started typing while driving with big fat thumb. Got me excited .

$NVAX "Merck has implemented a multi-layered strategy to turn the Keytruda transition into what it views as a manageable “hill” rather than a sharp revenue cliff. That includes accelerating internal research and also funneling $65 billion in external acquisitions and licensing agreements over the five years to build its pipeline of next-generation medicines." "The idea is to train the immune system to recognize and kill those unique cancer markers and then pair that response with Merck’s blockbuster immunotherapy Keytruda, which aims to help the body attack the cancer more effectively." https://www.cnbc.com/2026/10/14/merck-moderna-cancer-vaccine-manufacturing-time.html

🚀 $NVAX IS A TICKING TIME BOMB! 💣 🔥 28.37% SHORT FLOAT 🔥 8+ DAYS TO COVER One major catalyst could trigger a MASSIVE SHORT SQUEEZE! 📈🚀 SHORTS, ARE YOU READY? 🩳🔥

$NVAX ALL POTENTIAL CATALYSTS 🚀 💰 Sanofi CiC Phase 3 initiation → $125M milestone 💰 Sanofi technology transfer → $75M milestone expected in 2027 💉 Sanofi Nuvaxovid sales → Growing global royalties 🤝 Pfizer Matrix-M programs → Up to $500M in potential milestones across two programs 🚀 New partner for NVAX's own CiC vaccine → Potential major upfront payment + milestones + royalties 🧬 Matrix-M oncology licensing deal → Potential Big Pharma partnership 🔬 Additional Matrix-M licensing agreements → Infectious diseases and beyond 🦠 Sanofi H5 pandemic influenza program → Clinical progress and potential milestones 💊 C. difficile vaccine → Potential clinical entry in 2027 🧪 Shingles and RSV combination vaccines → Future partnership opportunities 🌍 R21/Matrix-M malaria vaccine → Growing global demand and royalties 📉 Aggressive cost reductions → Lower cash burn and improved profitability outlook

$NVAX Someone is working hard to keep things under control and prevent the stock from skyrocketing... it’s incredible how it can climb nearly 4% in 20 minutes, only to wipe out those entire gains in five minutes and flip into the red. Absolute algorithmic price manipulation.